Division of Global HIV/AIDS and Tuberculosis, Center for Global Health, US Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.
Health Systems Research Unit, South African Medical Research Council (HSRU, SAMRC), Pretoria, South Africa.
BMC Infect Dis. 2019 Sep 16;19(Suppl 1):789. doi: 10.1186/s12879-019-4341-4.
Despite improved policies to prevent mother-to-child HIV transmission (MTCT), adherence to maternal antiretroviral therapy (ART) and infant Nevirapine prophylaxis (NVP) is low in South Africa. We describe ART adherence amongst a cohort of HIV-positive mothers and HIV-exposed but uninfected infants from 6 weeks until 18 months post-delivery and identify risk factors for nonadherence.
Data were collected in 2012-2014 through a nationally representative survey of PMTCT effectiveness. Mother-infant pairs were enrolled during the infant's first immunization visit at 6 weeks. Mothers and HIV-exposed infants (2811 pairs) were followed to 18 months at 3-month intervals. Mothers who self-reported being on ART at 6 weeks postpartum (N = 1572 (55.9%)) and infants on NVP at 6 weeks (N = 2370 (84.3%)) were eligible for this analysis and information about their adherence was captured at each interview they attended thereafter. We defined nonadherence within each 3-month interval as self-report of missing > 5% of daily ART/NVP doses, estimated adherence using a Cox survival curve with Andersen & Gill setup for recurring events, and identified risk factors for nonadherence with an extended Cox regression model (separately for mothers and infants) in Stata 13. Results are not nationally representative as this is a subgroup analysis of the follow-up cohort.
Amongst mothers on ART at 6 weeks postpartum, cumulative adherence to maternal ART until 18 months was 63.4%. Among infants on NPV at 6 weeks postpartum, adherence to NVP was 74.5%.. Risk factors for nonadherence to maternal ART, controlling for other factors, included mother's age (16-24 years vs. ≥34 years, adjusted Hazard Ratio (aHR): 1.9, 95% CI: 1.4-2.5), nondisclosure of HIV status to anyone (nondisclosure vs. disclosure: aHR: 1.7, 95% CI: 1.3-2.1), and timing of ART initiation (initiated ART after delivery vs. initiated ART before delivery: aHR: 1.6, 95% CI: 1.3-2.0). Provincial variation was seen in nonadherence to infant NVP, controlling for other factors.
Maintaining ART adherence until 18 months postpartum remains a crucial challenge, with maternal ART adherence among the six week maternal ART cohort below 65% and infant NVP adherence among breastfeeding infants in this cohort below 75%.This is gravely concerning, given the global policy shift to lifelong ART amongst pregnant and lactating women, and the need for extended infant prophylaxis amongst mothers who are not virally suppressed. Our findings suggest that young mothers and mothers who do not disclose their status should be targeted with messages to improve adherence, and that late maternal ART initiation (after delivery) increases the risk of maternal nonadherence.
尽管已经出台了改善措施来预防母婴传播 HIV(MTCT),但南非的母婴抗逆转录病毒疗法(ART)和婴儿奈韦拉平预防(NVP)的依从性仍然很低。我们描述了从分娩后 6 周到 18 个月的 HIV 阳性母亲和 HIV 暴露但未感染婴儿队列中的 ART 依从性,并确定了不依从的风险因素。
数据是通过对 PMTCT 效果的全国代表性调查于 2012-2014 年收集的。母婴对在婴儿 6 周龄时第一次免疫接种时入组。在 3 个月的间隔内,对母亲和 HIV 暴露的婴儿(2811 对)进行随访至 18 个月。在产后 6 周时报告正在接受 ART(N = 1572(55.9%))和在 6 周时报告接受 NVP(N = 2370(84.3%))的母亲和婴儿有资格进行此分析,并在他们此后参加的每次访谈中记录他们的依从性信息。我们在每个 3 个月的间隔内将不依从定义为报告漏服大于每日 ART/NVP 剂量的 5%,使用 Cox 生存曲线和 Andersen & Gill 方法对复发事件进行估计,并使用 Stata 13 中的扩展 Cox 回归模型(分别针对母亲和婴儿)确定不依从的风险因素。由于这是随访队列的亚组分析,因此结果不具有全国代表性。
在产后 6 周接受 ART 的母亲中,直到 18 个月时,母亲 ART 的累积依从率为 63.4%。在产后 6 周接受 NVP 的婴儿中,NVP 的依从率为 74.5%。不依从母亲 ART 的风险因素,在控制其他因素后,包括母亲的年龄(16-24 岁与≥34 岁,调整后的危险比(aHR):1.9,95%CI:1.4-2.5)、向任何人隐瞒 HIV 状况(不隐瞒与隐瞒:aHR:1.7,95%CI:1.3-2.1)和 ART 开始时间(分娩后开始 ART 与分娩前开始 ART:aHR:1.6,95%CI:1.3-2.0)。在控制其他因素后,婴儿 NVP 的不依从与省级差异有关。
维持产后 18 个月的 ART 依从性仍然是一个关键挑战,6 周产妇 ART 队列中产妇 ART 依从性低于 65%,母乳喂养婴儿中婴儿 NVP 依从性低于 75%。这令人深感担忧,因为全球政策已经转向为孕妇和哺乳期妇女提供终生 ART,并且需要为未抑制病毒的母亲提供延长婴儿预防措施。我们的研究结果表明,应针对年轻母亲和不透露其身份的母亲开展提高依从性的宣传活动,并且产后(分娩后)开始接受 ART 会增加母亲不依从的风险。